Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial


Schoser B., Kishnani P., Kushlaf H., Ladha S., Mozaffar T., Straub V., ...More

NEUROMUSCULAR DISORDERS, vol.32, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Abstract
  • Volume: 32
  • Publication Date: 2022
  • Journal Name: NEUROMUSCULAR DISORDERS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Hacettepe University Affiliated: Yes